Americas COVID-19 Testing Market - Research and Markets

This recent study offers America’s COVID-19 testing analysis for an opportunity assessment for 2021-2031. The report consists of a comprehensive assessment of the most important market dynamics.

On conducting thorough research on the historical as well as current growth parameters of the Americas COVID-19 testing market, growth prospects of the market are obtained with maximum precision.

The report features unique and salient factors that may make a huge impact on the development of the Americas COVID-19 testing market during the forecast period. It can help market players to strategies their manufacturing and marketing strategies to envisage maximum growth in the Americas COVID-19 testing market in the coming years.

The report provides detailed information about the current and future growth prospects of the Americas COVID-19 testing market in the most comprehensive way for better understanding of readers.

Key Segments of Americas COVID-19 Testing Market

The publisher's study on the Americas COVID-19 testing market offers information divided into four important segments - Test type, Sample type, distribution channel and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Test type

SARS-CoV-2 IgM/IgG Antibody Rapid Test Kits
SARS-CoV-2 Antigen Rapid Test Kits
Multiplex Real-Time RT-PCR Assay Kits

Sample type

Blood
Nasopharyngeal Swabs

Distribution Channel

Hospital Pharmacies
Diagnostic Laboratories
Retail Pharmacies
Drug Store
Online Sales Channels

Region

North America
Latin America

Report Chapters:

Chapter 1 - Executive Summary

The report commences with the executive summary of the Americas COVID-19 testing market report, which includes the summary of key findings and statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the Americas COVID-19 testing market as well as the key trends impacting the market.

Chapter 2 - Market Overview

Readers can find detailed taxonomy and product definitions of the Americas COVID-19 testing market, in this chapter, which help readers, understand basic information about Americas COVID-19 testing.

Chapter 3 - Key Market Trends

This section highlights the key trends impacting the Americas COVID-19 testing market, which will help readers understand the current trends and their impact on market growth.

Chapter 4 - Market Background

This section tells us about micro and macro-economic factors that affect the market. And the drivers, restrain and future opportunities in this market and the growth of market in Americas COVID-19 testing sector. In addition, the Americas GDP and health care expenditure affect the market.

Chapter 5 - Americas COVID-19 testing Market Demand (in Volume Units) Analysis Forecast, 2021-2031

This section explains the Americas market volume analysis and forecast for the Americas COVID-19 testing during the forecast period. Along with the historical market and opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2020), and an incremental $ opportunity for the forecast period (2021-2031).

Chapter 6 - Americas COVID-19 testing Market - Pricing Analysis

This section explains the Americas market pricing analysis and forecast for the Americas COVID-19 testing during the forecast period.

Chapter 7 - Americas COVID-19 testing Market Demand (Size in US$ Mn) Analysis Forecast, 2021-2031

This section explains the Americas market value analysis and forecast for the Americas COVID-19 testing during the forecast period. Along with the historical market and opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2020), and an incremental $ opportunity for the forecast period (2021-2031).

Chapter 8 - Americas COVID-19 testing Market Analysis Opportunity Assessment (2021-2031), By Test type

Based on test type, the Americas COVID-19 testing market is segmented into key products commercially available, (SARS-CoV-2 IgM/IgG antibody rapid test kits, SARS-CoV-2 antigen rapid test kits, and multiplex real-time RT-PCR assay kits). In this chapter, readers can find information about a detailed analysis of the market by different treatment of Americas COVID-19 testing and their growth over the forecast period.

Chapter 9 - Americas COVID-19 testing Market Analysis Opportunity Assessment, 2021-2031, By Sample Type

Based on sample type, the Americas COVID-19 testing market is segmented into blood and nasopharyngeal swabs. In this chapter, readers can find information on market attractive analysis based on key target features of the product.

Chapter 10 - Americas COVID-19 testing Market Analysis Opportunity Assessment, 2021-2031, By Distribution Channel

Based on distribution channel, the Americas COVID-19 testing market is segmented into hospital pharmacy, Diagnostic Laboratories, retail pharmacies, online sales channel, and drug stores. In this chapter, readers can find information on market attractive analysis based on key materials.

Chapter 11 - Americas COVID-19 testing Market Analysis Opportunity Assessment 2021-2031, By Region

This chapter explains how the Americas COVID-19 testing market will grow across geographic regions including North America and Latin America.

Chapter 12 - U.S. COVID-19 testing Devices Market Analysis Opportunity Assessment 2021-2031

This chapter includes a detailed analysis of the growth of the U.S. Americas COVID-19 testing market. Readers can also find key takeaways of this region, and market growth based on Test type, sample type, distribution channel and region.

Chapter 13 - Canada COVID-19 testing Market Analysis Opportunity Assessment 2021-2031

This chapter includes the growth prospects of the Americas COVID-19 testing market in Canada. Readers can find thorough information about the growth parameters of the Canada Americas COVID-19 testing market during 2021-2031.

Chapter 14 - Latin Americas COVID-19 testing Market Analysis Opportunity Assessment 2021-2031

Important growth prospects of the Americas COVID-19 testing market based on test type, sample type, distribution channel and region and country in several Latin America countries are included in this chapter.

Chapter 15 - Market Structure Analysis

This chapter covers the market analysis of competitors based on revenue tiers, single point view of portfolio across industry segments, and their relative market position.

Chapter 16 - Competition Analysis

In this chapter, readers can find a comprehensive list of all the leading stakeholders in the Americas COVID-19 testing market, along with detailed information about each company, including company overview, revenue shares, strategic overview, and recent company developments.

Players featured in the Americas COVID-19 testing market report are Sky Medical Supplies & Equipment LLC., Sugentech, Inc., Novacyt Group, Aurora Instruments Ltd., PRIMA Lab SA, SD Biosensor, INC., Gold Standard Diagnostics, Eurofins Technologies, Biomerieux SA, and Danaher

Chapter 17 - Assumptions and Acronyms Used

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.

Chapter 18 - Research Methodology

This chapter helps readers understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about the autoclaves market.

1. Executive Summary

1.1. America’s Market Outlook
1.2. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion & Exclusion

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends

4. Market Background

4.1. Macro-Economic Factors
4.1.1. GDP Growth Outlook
4.1.2. America’s Healthcare Industry Outlook
4.1.3. America’s Pharmaceutical Market Expenditure
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity Analysis

5. America’s COVID-19 testing Market Volume (Units) Analysis Forecast, 2021-2031

5.1. Historical Market Volume (Units) Analysis, 2016-2020
5.2. Current and Future Market Volume (Units) Projections, 2021-2031
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis

6. America’s COVID-19 testing Market - Pricing Analysis

6.1. Country Pricing Analysis by Test Type
6.2. Pricing Break-up
6.2.1. Manufacturer Level Pricing
6.2.2. Distributor Level Pricing
6.3. Latin America and Middle East Average Pricing Analysis Benchmark

7. America’s COVID-19 testing Market Value Analysis Forecast, 2021-2031

7.1. Historical Market Value (US$ Mn) Analysis, 2016-2020
7.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis

8. America’s COVID-19 testing Market Analysis Forecast 2021-2031, by Test Type

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis by Product Type, 2016-2020
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Product Type, 2021-2031
8.3.1. SARS-CoV-2 IgM/IgG Antibody Rapid Test Kits
8.3.2. SARS-CoV-2 Antigen Rapid Test Kits
8.3.3. Multiplex Real-Time RT-PCR Assay Kits
8.4. Market Attractiveness Analysis by Test Type

9. America’s COVID-19 testing Market Analysis Forecast 2021-2031, by Sample Type

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis by Sample Type, 2016-2020
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Sample Type, 2021-2031
9.3.1. Blood
9.3.2. Nasopharyngeal Swabs
9.4. Market Attractiveness Analysis by Sample Type

10. America’s COVID-19 testing Market Analysis Forecast 2021-2031, By Distribution Channel

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2016-2020
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2021-2031
10.3.1. Hospital Pharmacies
10.3.2. Diagnostic Laboratories
10.3.3. Retail Pharmacies
10.3.4. Drug Store
10.3.5. Online Sales Channels
10.4. Market Attractiveness Analysis by Distribution Channel

11. America’s COVID-19 testing Market Analysis Forecast 2021-2031, by Region

11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Region, 2016-2020
11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021-2031
11.3.1. North America
11.3.2. Latin America
11.4. Market Attractiveness Analysis By Region

12. U.S. COVID-19 testing Market Analysis Forecast 2021-2031

12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
12.3.1. By Test Type
12.3.2. By Sample Type
12.3.3. By Distribution Channel
12.4. Market Attractiveness Analysis
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis

13. Canada COVID-19 testing Market Analysis Forecast 2021-2031

13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
13.3.1. By Test Type
13.3.2. By Sample Type
13.3.3. By Distribution Channel
13.4. Market Attractiveness Analysis
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis

14. Latin America COVID-19 testing Market Analysis Forecast 2021-2031

14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021-2031
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.2. By Test Type
14.3.3. By Sample Type
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis

15. Market Structure Analysis

15.1. Market Analysis by Tier of Companies
15.2. Market Concentration
15.3. Market Share Analysis of Top Players
15.4. Market Presence Analysis
15.4.1. By Regional Foot Print of Players
15.4.2. Product Foot Print by Players
15.4.3. Channel Foot Print by Players

16. Competition Analysis

16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Competition Deep Dive
16.3.1. Biolidics Limited
16.3.1.1. Overview
16.3.1.2. Product Portfolio
16.3.1.3. Analyst Commentary
16.3.1.4. Key Financials
16.3.1.5. Recent Developments
16.3.1.6. Sales Footprint
16.3.1.7. Strategy Overview
16.3.1.7.1. Marketing Strategy
16.3.1.7.2. Product Strategy
16.3.1.7.3. Channel Strategy
16.3.2. Sky Medical Supplies & Equipment LLC
16.3.2.1. Overview
16.3.2.2. Product Portfolio
16.3.2.3. Analyst Commentary
16.3.2.4. Key Financials
16.3.2.5. Recent Developments
16.3.2.6. Sales Footprint
16.3.2.7. Strategy Overview
16.3.2.7.1. Marketing Strategy
16.3.2.7.2. Product Strategy
16.3.2.7.3. Channel Strategy
16.3.3. Sugentech, Inc.
16.3.3.1. Overview
16.3.3.2. Product Portfolio
16.3.3.3. Analyst Commentary
16.3.3.4. Key Financials
16.3.3.5. Recent Developments
16.3.3.6. Sales Footprint
16.3.3.7. Strategy Overview
16.3.3.7.1. Marketing Strategy
16.3.3.7.2. Product Strategy
16.3.3.7.3. Channel Strategy
16.3.4. Novacyt Group
16.3.4.1. Overview
16.3.4.2. Product Portfolio
16.3.4.3. Analyst Commentary
16.3.4.4. Key Financials
16.3.4.5. Recent Developments
16.3.4.6. Sales Footprint
16.3.4.7. Strategy Overview
16.3.4.7.1. Marketing Strategy
16.3.4.7.2. Product Strategy
16.3.4.7.3. Channel Strategy
16.3.5. Aurora Instruments Ltd.
16.3.5.1. Overview
16.3.5.2. Product Portfolio
16.3.5.3. Analyst Commentary
16.3.5.4. Key Financials
16.3.5.5. Recent Developments
16.3.5.6. Sales Footprint
16.3.5.7. Strategy Overview
16.3.5.7.1. Marketing Strategy
16.3.5.7.2. Product Strategy
16.3.5.7.3. Channel Strategy
16.3.6. Glenbio Ltd
16.3.6.1. Overview
16.3.6.2. Product Portfolio
16.3.6.3. Analyst Commentary
16.3.6.4. Key Financials
16.3.6.5. Recent Developments
16.3.6.6. Sales Footprint
16.3.6.7. Strategy Overview
16.3.6.7.1. Marketing Strategy
16.3.6.7.2. Product Strategy
16.3.6.7.3. Channel Strategy
16.3.7. PRIMA Lab SA
16.3.7.1. Overview
16.3.7.2. Product Portfolio
16.3.7.3. Analyst Commentary
16.3.7.4. Key Financials
16.3.7.5. Recent Developments
16.3.7.6. Sales Footprint
16.3.7.7. Strategy Overview
16.3.7.7.1. Marketing Strategy
16.3.7.7.2. Product Strategy
16.3.7.7.3. Channel Strategy
16.3.8. SD Biosensor, INC.
16.3.8.1. Overview
16.3.8.2. Product Portfolio
16.3.8.3. Analyst Commentary
16.3.8.4. Key Financials
16.3.8.5. Recent Developments
16.3.8.6. Sales Footprint
16.3.8.7. Strategy Overview
16.3.8.7.1. Marketing Strategy
16.3.8.7.2. Product Strategy
16.3.8.7.3. Channel Strategy
16.3.9. Gold Standard Diagnostics
16.3.9.1. Overview
16.3.9.2. Product Portfolio
16.3.9.3. Analyst Commentary
16.3.9.4. Key Financials
16.3.9.5. Recent Developments
16.3.9.6. Sales Footprint
16.3.9.7. Strategy Overview
16.3.9.7.1. Marketing Strategy
16.3.9.7.2. Product Strategy
16.3.9.7.3. Channel Strategy
16.3.10. Eurofins Technologies
16.3.10.1. Overview
16.3.10.2. Product Portfolio
16.3.10.3. Analyst Commentary
16.3.10.4. Key Financials
16.3.10.5. Recent Developments
16.3.10.6. Sales Footprint
16.3.10.7. Strategy Overview
16.3.10.7.1. Marketing Strategy
16.3.10.7.2. Product Strategy
16.3.10.7.3. Channel Strategy
16.3.11. myLAB Box
16.3.11.1. Overview
16.3.11.2. Product Portfolio
16.3.11.3. Analyst Commentary
16.3.11.4. Key Financials
16.3.11.5. Recent Developments
16.3.11.6. Sales Footprint
16.3.11.7. Strategy Overview
16.3.11.7.1. Marketing Strategy
16.3.11.7.2. Product Strategy
16.3.11.7.3. Channel Strategy
16.3.12. Biomerieux SA
16.3.12.1. Overview
16.3.12.2. Product Portfolio
16.3.12.3. Analyst Commentary
16.3.12.4. Key Financials
16.3.12.5. Recent Developments
16.3.12.6. Sales Footprint
16.3.12.7. Strategy Overview
16.3.12.7.1. Marketing Strategy
16.3.12.7.2. Product Strategy
16.3.12.7.3. Channel Strategy
16.3.13. Danaher
16.3.13.1. Overview
16.3.13.2. Product Portfolio
16.3.13.3. Analyst Commentary
16.3.13.4. Key Financials
16.3.13.5. Recent Developments
16.3.13.6. Sales Footprint
16.3.13.7. Strategy Overview
16.3.13.7.1. Marketing Strategy
16.3.13.7.2. Product Strategy
16.3.13.7.3. Channel Strategy
16.3.14. F. Hoffmann-La Roche Ltd
16.3.14.1. Overview
16.3.14.2. Product Portfolio
16.3.14.3. Analyst Commentary
16.3.14.4. Key Financials
16.3.14.5. Recent Developments
16.3.14.6. Sales Footprint
16.3.14.7. Strategy Overview
16.3.14.7.1. Marketing Strategy
16.3.14.7.2. Product Strategy
16.3.14.7.3. Channel Strategy
16.3.15. Qiagen NV
16.3.15.1. Overview
16.3.15.2. Product Portfolio
16.3.15.3. Analyst Commentary
16.3.15.4. Key Financials
16.3.15.5. Recent Developments
16.3.15.6. Sales Footprint
16.3.15.7. Strategy Overview
16.3.15.7.1. Marketing Strategy
16.3.15.7.2. Product Strategy
16.3.15.7.3. Channel Strategy
16.3.16. Abbott
16.3.16.1. Overview
16.3.16.2. Product Portfolio
16.3.16.3. Analyst Commentary
16.3.16.4. Key Financials
16.3.16.5. Recent Developments
16.3.16.6. Sales Footprint
16.3.16.7. Strategy Overview
16.3.16.7.1. Marketing Strategy
16.3.16.7.2. Product Strategy
16.3.16.7.3. Channel Strategy
16.3.17. Thermo Fisher Scientific Inc
16.3.17.1. Overview
16.3.17.2. Product Portfolio
16.3.17.3. Analyst Commentary
16.3.17.4. Key Financials
16.3.17.5. Recent Developments
16.3.17.6. Sales Footprint
16.3.17.7. Strategy Overview
16.3.17.7.1. Marketing Strategy
16.3.17.7.2. Product Strategy
16.3.17.7.3. Channel Strategy

17. Assumptions and Acronyms Used

18. Research Methodology

16.3.2.3. Analyst Commentary
16.3.2.4. Key Financials
16.3.2.5. Recent Developments
16.3.2.6. Sales Footprint
16.3.2.7. Strategy Overview
16.3.2.7.1. Marketing Strategy
16.3.2.7.2. Product Strategy
16.3.2.7.3. Channel Strategy
16.3.3. Sugentech, Inc.
16.3.3.1. Overview
16.3.3.2. Product Portfolio
16.3.3.3. Analyst Commentary
16.3.3.4. Key Financials
16.3.3.5. Recent Developments
16.3.3.6. Sales Footprint
16.3.3.7. Strategy Overview
16.3.3.7.1. Marketing Strategy
16.3.3.7.2. Product Strategy
16.3.3.7.3. Channel Strategy
16.3.4. Novacyt Group
16.3.4.1. Overview
16.3.4.2. Product Portfolio
16.3.4.3. Analyst Commentary
16.3.4.4. Key Financials
16.3.4.5. Recent Developments
16.3.4.6. Sales Footprint
16.3.4.7. Strategy Overview
16.3.4.7.1. Marketing Strategy
16.3.4.7.2. Product Strategy
16.3.4.7.3. Channel Strategy
16.3.5. Aurora Instruments Ltd.
16.3.5.1. Overview
16.3.5.2. Product Portfolio
16.3.5.3. Analyst Commentary
16.3.5.4. Key Financials
16.3.5.5. Recent Developments
16.3.5.6. Sales Footprint
16.3.5.7. Strategy Overview
16.3.5.7.1. Marketing Strategy
16.3.5.7.2. Product Strategy
16.3.5.7.3. Channel Strategy
16.3.6. Glenbio Ltd
16.3.6.1. Overview
16.3.6.2. Product Portfolio
16.3.6.3. Analyst Commentary
16.3.6.4. Key Financials
16.3.6.5. Recent Developments
16.3.6.6. Sales Footprint
16.3.6.7. Strategy Overview
16.3.6.7.1. Marketing Strategy
16.3.6.7.2. Product Strategy
16.3.6.7.3. Channel Strategy
16.3.7. PRIMA Lab SA
16.3.7.1. Overview
16.3.7.2. Product Portfolio
16.3.7.3. Analyst Commentary
16.3.7.4. Key Financials
16.3.7.5. Recent Developments
16.3.7.6. Sales Footprint
16.3.7.7. Strategy Overview
16.3.7.7.1. Marketing Strategy
16.3.7.7.2. Product Strategy
16.3.7.7.3. Channel Strategy
16.3.8. SD Biosensor, INC.
16.3.8.1. Overview
16.3.8.2. Product Portfolio
16.3.8.3. Analyst Commentary
16.3.8.4. Key Financials
16.3.8.5. Recent Developments
16.3.8.6. Sales Footprint
16.3.8.7. Strategy Overview
16.3.8.7.1. Marketing Strategy
16.3.8.7.2. Product Strategy
16.3.8.7.3. Channel Strategy
16.3.9. Gold Standard Diagnostics
16.3.9.1. Overview
16.3.9.2. Product Portfolio
16.3.9.3. Analyst Commentary
16.3.9.4. Key Financials
16.3.9.5. Recent Developments
16.3.9.6. Sales Footprint
16.3.9.7. Strategy Overview
16.3.9.7.1. Marketing Strategy
16.3.9.7.2. Product Strategy
16.3.9.7.3. Channel Strategy
16.3.10. Eurofins Technologies
16.3.10.1. Overview
16.3.10.2. Product Portfolio
16.3.10.3. Analyst Commentary
16.3.10.4. Key Financials
16.3.10.5. Recent Developments
16.3.10.6. Sales Footprint
16.3.10.7. Strategy Overview
16.3.10.7.1. Marketing Strategy
16.3.10.7.2. Product Strategy
16.3.10.7.3. Channel Strategy
16.3.11. myLAB Box
16.3.11.1. Overview
16.3.11.2. Product Portfolio
16.3.11.3. Analyst Commentary
16.3.11.4. Key Financials
16.3.11.5. Recent Developments
16.3.11.6. Sales Footprint
16.3.11.7. Strategy Overview
16.3.11.7.1. Marketing Strategy
16.3.11.7.2. Product Strategy
16.3.11.7.3. Channel Strategy
16.3.12. Biomerieux SA
16.3.12.1. Overview
16.3.12.2. Product Portfolio
16.3.12.3. Analyst Commentary
16.3.12.4. Key Financials
16.3.12.5. Recent Developments
16.3.12.6. Sales Footprint
16.3.12.7. Strategy Overview
16.3.12.7.1. Marketing Strategy
16.3.12.7.2. Product Strategy
16.3.12.7.3. Channel Strategy
16.3.13. Danaher
16.3.13.1. Overview
16.3.13.2. Product Portfolio
16.3.13.3. Analyst Commentary
16.3.13.4. Key Financials
16.3.13.5. Recent Developments
16.3.13.6. Sales Footprint
16.3.13.7. Strategy Overview
16.3.13.7.1. Marketing Strategy
16.3.13.7.2. Product Strategy
16.3.13.7.3. Channel Strategy
16.3.14. F. Hoffmann-La Roche Ltd
16.3.14.1. Overview
16.3.14.2. Product Portfolio
16.3.14.3. Analyst Commentary
16.3.14.4. Key Financials
16.3.14.5. Recent Developments
16.3.14.6. Sales Footprint
16.3.14.7. Strategy Overview
16.3.14.7.1. Marketing Strategy
16.3.14.7.2. Product Strategy
16.3.14.7.3. Channel Strategy
16.3.15. Qiagen NV
16.3.15.1. Overview
16.3.15.2. Product Portfolio
16.3.15.3. Analyst Commentary
16.3.15.4. Key Financials
16.3.15.5. Recent Developments
16.3.15.6. Sales Footprint
16.3.15.7. Strategy Overview
16.3.15.7.1. Marketing Strategy
16.3.15.7.2. Product Strategy
16.3.15.7.3. Channel Strategy
16.3.16. Abbott
16.3.16.1. Overview
16.3.16.2. Product Portfolio
16.3.16.3. Analyst Commentary
16.3.16.4. Key Financials
16.3.16.5. Recent Developments
16.3.16.6. Sales Footprint
16.3.16.7. Strategy Overview
16.3.16.7.1. Marketing Strategy
16.3.16.7.2. Product Strategy
16.3.16.7.3. Channel Strategy
16.3.17. Thermo Fisher Scientific Inc
16.3.17.1. Overview
16.3.17.2. Product Portfolio
16.3.17.3. Analyst Commentary
16.3.17.4. Key Financials
16.3.17.5. Recent Developments
16.3.17.6. Sales Footprint
16.3.17.7. Strategy Overview
16.3.17.7.1. Marketing Strategy
16.3.17.7.2. Product Strategy
16.3.17.7.3. Channel Strategy

17. Assumptions and Acronyms Used18. Research Methodology

Companies Mentioned

Abbott
Aurora Instruments Ltd.
Biolidics Limited
Biomerieux SA
Danaher
Eurofins Technologies
F. Hoffmann-La Roche Ltd
Glenbio Ltd
Gold Standard Diagnostics
myLAB Box
Novacyt Group
PRIMA Lab SA
Qiagen NV
SD Biosensor, INC.
Sky Medical Supplies & Equipment LLC
Sugentech, Inc.
Thermo Fisher Scientific Inc